HER2 amplification or overexpression is observed in about 2–6% of patients with advanced or metastatic colorectal cancer (CRC), but its prevalence is higher in RAS/BRAF-wild-type tumors with 5–14% [73,77,116]. Here, ERBB2 is linked to metastatic colorectal cancer.